Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Collegium Pharmaceutical (COLL) Change in Receivables: 2016-2025

Historic Change in Receivables for Collegium Pharmaceutical (COLL) over the last 9 years, with Sep 2025 value amounting to $20.9 million.

  • Collegium Pharmaceutical's Change in Receivables rose 10913.68% to $20.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.3 million, marking a year-over-year increase of 142.07%. This contributed to the annual value of $4.4 million for FY2024, which is 222.82% up from last year.
  • As of Q3 2025, Collegium Pharmaceutical's Change in Receivables stood at $20.9 million, which was up 233.47% from -$15.7 million recorded in Q2 2025.
  • In the past 5 years, Collegium Pharmaceutical's Change in Receivables ranged from a high of $58.9 million in Q3 2021 and a low of -$43.2 million during Q4 2021.
  • Moreover, its 3-year median value for Change in Receivables was -$106,000 (2024), whereas its average is $567,000.
  • In the last 5 years, Collegium Pharmaceutical's Change in Receivables slumped by 729.63% in 2021 and then soared by 10,913.68% in 2025.
  • Over the past 5 years, Collegium Pharmaceutical's Change in Receivables (Quarterly) stood at -$43.2 million in 2021, then skyrocketed by 71.54% to -$12.3 million in 2022, then surged by 81.06% to -$2.3 million in 2023, then surged by 95.44% to -$106,000 in 2024, then skyrocketed by 10,913.68% to $20.9 million in 2025.
  • Its Change in Receivables stands at $20.9 million for Q3 2025, versus -$15.7 million for Q2 2025 and $170,000 for Q1 2025.